Flat-fixed dosing versus body surface area based dosing of anticancer drugs in adults: does it make a difference?
about
Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancerCovariate pharmacokinetic model building in oncology and its potential clinical relevance.Urinary excretion of platinum, arsenic and selenium of cancer patients from the Antofagasta region in Chile treated with platinum-based drugsMagnesium, zinc, arsenic, selenium and platinum urinary excretion from cancer patients of Antofagasta region, Chile: multi-metal approachIntegrated analysis of preclinical data to support the design of the first in man study of LY2181308, a second generation antisense oligonucleotide.Population pharmacokinetics of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (Triapine®) in cancer patients.Neutrophil-guided dosing of anthracycline-cyclophosphamide-containing chemotherapy in patients with breast cancer: a feasibility study.Switching from body surface area-based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis.Phase I and pharmacological study of pazopanib in combination with oral topotecan in patients with advanced solid tumours.Dose banding as an alternative to body surface area-based dosing of chemotherapeutic agentsOral treatment with etoposide in small cell lung cancer - dilemmas and solutions.Advances in cancer therapeuticsA guide to rational dosing of monoclonal antibodies.Chemotherapy dosing in overweight and obese patients with cancer.Role of subcutaneous formulation of trastuzumab in the treatment of patients with HER2-positive breast cancer.Fixed Dosing of Monoclonal Antibodies in Oncology.Decreased gastrointestinal toxicity associated with a novel capecitabine schedule (7 days on and 7 days off): a systematic review.Clinically Relevant Concentrations of Anticancer Drugs: A Guide for Nonclinical Studies.Dose selection for the investigational anticancer agent alisertib (MLN8237): Pharmacokinetics, pharmacodynamics, and exposure-safety relationships.Comparison of two different formulas for body surface area in adults at extremes of height and weight.Population pharmacokinetics of kahalalide F in advanced cancer patients.Population Pharmacokinetics of ABT-806, an Investigational Anti-Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody, in Advanced Solid Tumor Types Likely to Either Over-Express Wild-Type EGFR or Express Variant III Mutant EGFR.Therapeutic drug monitoring and tyrosine kinase inhibitors.Nanomedicine Faces Barriers.Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trials.Individualized dosing with axitinib: rationale and practical guidance.Clinical Pharmacology Considerations for the Development of Immune Checkpoint Inhibitors.Pembrolizumab as first-line therapy for metastatic non-small-cell lung cancer.Investigating the potential impact of dose banding for systemic anti-cancer therapy in the paediatric setting based on pharmacokinetic evidence.Anatomical and physiological basis for the allometric scaling of cisplatin clearance in dogs.The oncology pharmacy in cancer care delivery in a resource-constrained setting in western Kenya.Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC).Dose calculation of anticancer drugsObesity and cancer
P2860
Q26775949-FCC9822E-F983-4BF3-8AF2-9CB6472A3960Q27687599-DD85E6B4-44B0-4362-B3A4-9AAFC415AAD0Q28388226-D5E2059F-EF40-479F-80AD-874C4AA4B235Q28391017-051C4CEC-12DE-46DC-B157-85C613094FE3Q33809839-1355B42E-7DCA-4931-9847-D02222C81B6AQ34685780-B8A54060-BF19-4657-9462-3A1935B31DD3Q35171432-4EDEFD93-A2FF-4322-B317-9242F77C4F12Q35557435-F11E3F38-A9F0-475B-BD44-3190C233A985Q36027042-4DA98992-B8DF-4080-9279-00412762A57AQ36287956-97045E51-0383-4BC4-9CDE-6460E1E1FDDDQ36613874-4D5803CA-027D-4289-8327-7EE119C3E089Q37069339-E0863D64-B394-42D8-A142-29A59104CEDDQ37976878-D13CC69E-2804-4872-8348-E65FE1C0C506Q38121735-1E380CCF-551E-4BCD-BAC2-3F3575ED08D8Q38257642-E0B21672-EED8-474B-8E53-FAAC4AA069B1Q38654371-4BE99E53-ACD9-48DF-8479-56605FAAFBEFQ38673003-C1027D7A-6A4C-42FD-8042-0A8384519ABBQ38863833-CEBBB9AB-EFFD-412C-9F75-3C7438A32B9CQ39115623-6122486A-3783-4023-8471-DC6476AC855BQ40523171-4BCE01D7-2C52-452B-8D0D-CA021B800346Q40816791-C248384F-0289-4827-BCE5-C5A4AEF59652Q41243702-643A8103-7C0F-45D7-8447-7B95A8B42B87Q41846251-97A83C7E-74A9-4213-9761-43FFFECD45AAQ46181824-DAD5F9F0-46C3-4B98-968C-F52BFC37E384Q46427740-290ADD42-3A55-4FDA-965C-AA1B1B7464F0Q47271327-3ABF5856-76FC-4C77-8FEF-969F4CE9183EQ47943881-FF896448-6CD9-41C9-90C8-2EB0587FCA7EQ49959323-13954B1D-DB18-480C-90D5-26E72712794DQ50043715-41FE8E2A-8F82-4282-879A-1ED9FF24EAB5Q50798269-A72D2D1E-402E-4C46-A6B2-829D09B701B0Q51450121-D63855A4-532C-4965-8872-A4886911C83BQ52848876-EAF41940-BE5A-47B6-BE5B-98EC39E36B48Q56391087-ABD24186-F0F9-435A-B99B-29F89DA77954Q57748968-89820888-9A24-44BD-8970-E77F096F6074
P2860
Flat-fixed dosing versus body surface area based dosing of anticancer drugs in adults: does it make a difference?
description
2007 nî lūn-bûn
@nan
2007 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Flat-fixed dosing versus body ...... ts: does it make a difference?
@ast
Flat-fixed dosing versus body ...... ts: does it make a difference?
@en
Flat-fixed dosing versus body ...... ts: does it make a difference?
@nl
type
label
Flat-fixed dosing versus body ...... ts: does it make a difference?
@ast
Flat-fixed dosing versus body ...... ts: does it make a difference?
@en
Flat-fixed dosing versus body ...... ts: does it make a difference?
@nl
prefLabel
Flat-fixed dosing versus body ...... ts: does it make a difference?
@ast
Flat-fixed dosing versus body ...... ts: does it make a difference?
@en
Flat-fixed dosing versus body ...... ts: does it make a difference?
@nl
P2093
P1433
P1476
Flat-fixed dosing versus body ...... ts: does it make a difference?
@en
P2093
Floris A de Jong
Jaap Verweij
Jessica M van der Bol
Ron H J Mathijssen
Walter J Loos
P304
P356
10.1634/THEONCOLOGIST.12-8-913
P577
2007-08-01T00:00:00Z